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INTRODUCTION
Ovarian carcinoma as a malignant tumor in women
after cervical and endometrial carcinoma has the
prevalence rate of 2.4-5.6%. This carcinoma causes
mortality higher than other malignant tumors. It is
because 70% of the cases is diagnosed in ad-
vanced stage (between stage III and IV) so that it
has spread far beyond the ovary. Therefore, there
is a need to find a highly effective screening tools
in ovarian malignant tumor to reduce the morbi-
dity and mortality of this disease.1,2 Excellent
screening tools has high both sensitivity and speci-
ficity.1 One of the antigens released from the ma-
lignancy of the epithelial ovarian cells is Ca-125.1
Approximately, 83% of patients with ovarian
malignant tumor had a high level of Ca-125, which
showing the value more than 35 U/ml.1,3 A study
conducted in Sweden stated that the specificity of
Ca-125 in ovarian malignant tumor was 97% and
the positive predictive value (PPV) was 4.6%. The
low level of PPV was caused by the elevation of
Ca-125 happened in several condition such as
other malignant tumors like breast, pancreas, blad-
der, lung and liver cancer; as well as in other be-
nign abnormalities including endometriosis, myo-
ma uteri, tuba-ovarian abscess, benign ovarian
cyst, ectopic pregnancy, diverticulitis; even in phy-
siological conditions for example pregnancy and
menstruation. Meanwhile, other tumor markers
that could be detected in ovarian malignancies in-
cluding Ca-19-9, Ca 15-3, Ca 72-4, LSA (lipid-asso-
ciated sialic acid), LPA (lysophosphatide acid),
osteopontin, and mesothelin.2,3
Abstract
Objective: To determine the sensitivity and specificity of mesothelin
compared with Ca-125 as a tumor marker in predicting ovarian ma-
lignancy.
Method: The cross sectional study design with diagnostic tests was
conducted in 30 samples of patients undergoing elective laparotomy
due to ovarian tumor. We compared the sensitivity and specificity
between mesothelin and Ca-125, then the data were analyzed using
SPSS software version 22.0.
Result: According to the ROC curve analysis, optimal sensitivity and
specificity value of mesothelin was 63.2% and 54.5% at a cut-off
point of 0.45 pg/ml; or 42.1% and 72.7% at a cut-off point of 0.55
pg/ml. While the value of both optimal sensitivity and specificity of
Ca-125 was 73.7% and 63.6% at a cut-off point of 46.63 U/ml.
Conclusion: Mesothelin and Ca-125 are not different significantly
for the AUC value of 50%. Due to higher sensitivity and specificity of
Ca-125 than mesothelin, Ca-125 is still used as tumor marker for
screening the ovarian malignancy.
[Indones J Obstet Gynecol 2016; 4-2: 107-110]
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Abstrak
Tujuan: Untuk menentukan sensitivitas dan spesifisitas mesothelin
dibandingkan dengan antigen Ca-125 sebagai penana tumor dalammemprediksi keganasan ovarium.
Metode: Studi potong lintang dengan uji diagnostic dilakukan pada30 pasien yang akan menjalankan laparotomy elektif karena tumor
ovarium. Kami akan membandingkan sensitivitas dan spesifisitas an-
tara mesotelin dan Ca-125. Data yang diperoleh kemudian dianalisisdengan menggunakan SPSS versi 22.0 dan dilakukan pembahasan se-
suai literatur yang ada.
Hasil: Berdasarkan analisis kurva ROC, sensitivitas dan spesifisitas
yang optimal pada mesothelin adalah 63,2% dan 54,5% dengan nilaicut-off 0,45 pg/ml dan 42,1% dan 72,7% dengan nilai cut off 0,55
pg/ml. Sedangkan, nilai sensitivitas optimal dan spesifisitas Ca-125
adalah 73,7% dan 63,3% dengan nilai cut-off 46,6 U/ml.
Kesimpulan: Mesotelin dan Ca-125 tidak berbeda bermakna padanilai kurva AUC 50%. Ca-125 memberikan nilai sensitivitas dan spesi-
fisitas lebih tinggi dari mesotelin sehingga Ca-125 masih digu-nakan
sebagai alat skrining keganasan ovarium.
[Maj Obstet Ginekol Indones 2016; 4-2: 107-110]
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Mesothelin as a 40-kDa glycoprotein is bound to
glucosilphosphatydillinositol. In normal tissues,
the expression of mesothelin can be found on the
mesothelial cells (cells that border the pleura, peri-
toneum and pericardium) and also epithelial cells
of the trachea, tonsils, fallopian tubes, and kid-
neys.4 According to study by Hough, et al. in 2000,
mesothelin was also expressed in ovarian carci-
noma. Thus, it usually used as a screening tool in
ovarian carcinoma.5 Lowe, et al. in their study
stated that increased levels of mesothelin were
higher in patients who had undergone optimal de-
bulking compared with those with advanced ova-
rian cancer.6,7 In addition, 42% of patients who
were at an early-stage of ovarian cancer also had
elevated levels of mesothelin in the urine com-
pared with only 12% of patients who had elevated
in mesothelin serum. This proved that mesothelin
had the potency as a screening tool to detect the
ovarian carcinoma.8
Based on recent literatures, we would like to de-
termine the relationship between mesothelin and
Ca-125 as screening tools for ovarian malignant
tumor.
METHODS
This cross sectional study to determine the diag-
nostic test was carried out in ovarian carcinoma
patients who were registered at the gynecology out
patient polyclinic in Prof. Dr. R. D. Kandou hospital.
The inclusion criterias were the patients diagnosed
as ovarian tumor, they would undergo the elective
laparotomy, also they did not suffer from other ma-
lignancies. If they would like to participate, they
had to sign the informed consent form. We ex-
cluded the patients who could not do the lapara-
tomy. Besides, the result of biospy showed the tu-
mor not original from the ovary was excluded. The
patients were checked the blood samples to show
the level of mesothelin. This examination was sent
to Prodia laboratory, Manado. This study was con-
ducted from June to August 2015.
By calculating using the formula, we had to full-
fill minimally 30 samples of ovarian carcinoma.
Data were analyzed by the ROC to calculate sensi-
tivity and specificity levels of mesothelin to the his-
topathology samples of ovarian carcinoma. The
data were processed using the software program
of Statistical Product and Service Solutions (SPSS)
for Windows version 22.0.
RESULTS
Of 30 patients included in this study, most of them
(18/50) were 40-59 years old and more than half
of patients (18/30) were multi parity (Table 1).
The histopathology characteristic of ovarian tu-
mors showed that 2 samples were serous cysta-
denoma and 10 samples were mucinous cysta-
denoma as the benign ovary tumors. Meanwhile,
ovarian serous cystadenocarcinoma was on 3 pa-
tients and the remaining was mucinous cystade-
nocarcinoma (15 samples) as malignant ovary tu-
mors. This examination was done at the Labora-
tory of Pathology Anatomy Faculty of Medicine
Universitas Sam Ratulangi, Manado.
Table 1. Characteristics of Respondents
Characteristics N (30)
Age <20 1
20-39 5
40-59 18
≥60 6
Parity 0 3
1-2 9
3-5 16
>5 2
BMI ≤18 3
18-24 14
≥25 13
Based on the statistical group, Ca-125 levels had
an average value of 412.0 U/dl with a standard de-
viation of 963.9. On the other hand, mesothelin lev-
els showed an average value of 1.5 pg/ml with a
standard deviation of 3.7 (figure 1). There was not
correlation between mesothelin and ovarian malig-
nant tumor (p=0.15; r=0.15).
From the ROC method above, we obtained
59.8% (95% CI 39.3-80.3%) for AUC values of
mesothelin. It meant that mesothelin levels were
not significantly different to the 50% value of AUC.
While, the AUC values of Ca-125 was 60.5% (95%
CI 38.3-80.3%) which meant that Ca-125 levels
were not significantly different from AUC value of
50%.
From the table of coordinates, sensitivity and
specificity for mesothelin levels with a "cut off
point" of 0.45 pg/ml were 63.2% and 54.5%;
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meanwhile, if we set up the "cut off point" of
mesothelin levels at 0.55 pg/ml, the sensitivity
and specificity would be 42.1% and 72.7%. The in-
terpretation was that 63.2% sensitivity values ob-
tained from this study was valid if mesothelin lev-
els of 0.45 pg/ml were used in 100 patients and
63 patients had mesothelin levels greater than or
equal to 0.45 pg/ml, they had epithelial ovarian
malignant tumor which confirmed through his-
topa-thology examination as a gold standard. This
was implied vice versa for the specificity.
DISCUSSION
Until 2010, ovarian cancer was still the third ma-
lignant diseases in women. According to study con-
ducted by Jemal, et al. in the United States, there
were an estimated of 21,880 new cases, whereas
13,850 patients passed away due to this disease.
In Indonesia itself, the ovarian cancer was ranked
the second after cervical cancer as the cause of gy-
necological cancer death. Nearly 70% of women
with ovarian cancer were diagnosed in advanced
stage so that the five-year survival rate was only
30%.2
In this study, the majority of patients were 40-
59 years old and most of them had three to five
children. According to another study, it was found
that the population of patients with ovarian tumors
were between 20 and 65 years old. This statement
was supported through study by Boy B et al and
Diana HF et al where they said that the ovarian
malignant tumor was rare under 40 years old.9,10
A little bit different result by Martin Siregar, et al,
they found that the distribution of patients with
ovarian malignant tumor were mostly in the age
group of 41 to 50 years old.11
Hala Abdel-Azeez, et al in their study reported
that the cut-off value for mesothelin was 1.4nM,
which meant that it had a lower sensitivity when
compared with Ca-125 in detecting ovarian malig-
nancies. Increased mesothelin levels in serum was
ranged from 60% to 77% in women with ovarian
cancer.12 Several studies investigated the use of Ca-
125 and mesothelin as single also combined mar-
kers in patients with ovarian malignancy. As a sin-
gle marker, Ca-125 had higher sensitivity than
mesothelin itself.14 Although mesothelin could not
be used as a single marker to detect ovarian cancer,
when combined with Ca-125, it resulted high sen-
sitivity. Serum mesothelin increased at a fraction
of patients with normal Ca-125 serum. The combi-
nation of Ca-125 and mesothelin would rise the
sensitivity compared with a single use of Ca-125 in
detecting the ovarian malignancy. According to
study by Badgwell, et al. in 2007, mesothelin in the
urine acted more sensitive marker than mesothe-
lin serum in the blood to differentiate patients with
early-stage of ovarian malignancy.7
Figure 1. The Graphs of Mesothelin and Ca-125 Level.
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CONCLUSION
We conclude that mesothelin and Ca-125 are not
significantly different to the AUC value of 50%. The
optimal sensitivity and specificity for mesothelin
was lower than the results shown by Ca-125.
Therefore, Ca-125 is still used as a tumor marker
for screening the ovarian malignancy.
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